Last reviewed · How we verify
MVA CS
At a glance
| Generic name | MVA CS |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Value of Linear Ablation Without Pulmonary Vein Isolation in Persistent Atrial Fibrillation (NA)
- CS DNA MVA Trial in Mampong, Ghana (PHASE1)
- Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men (PHASE1)
- A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates (PHASE1, PHASE2)
- A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1 (PHASE1, PHASE2)
- Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVA CS CI brief — competitive landscape report
- MVA CS updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI